Goldacre has focused on a British Medical Journal (BMJ) paper that claimed that, of the clinical trials completed by the industry in 2009, only 22% had reported results within one year of completion.
In the first paper (The Lancet), the authors studied individual patient data from 51 randomised trials of daily aspirin versus no aspirin to prevent vascular events such as heart attacks.
James de Lemos of the Univeristy of Texas Southwestern Medical Center, first author of the JAMA paper, says patients in A to Z were getting less-aggressive treatment than those in other trials.
The paper, which Nissen and Topol wrote with Kathy Wolski, a Cleveland Clinic statistician, combines results from five clinical trials of Pargluva in which the drug was compared to either placebo or other diabetes drugs.